Q1 Earnings Forecast for ACRV Issued By HC Wainwright

Acrivon Therapeutics, Inc. (NASDAQ:ACRV) – Investment analysts at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for Acrivon Therapeutics in a note issued to investors on Wednesday, March 26th. HC Wainwright analyst E. Bodnar expects that the company will post earnings per share of ($0.63) for the quarter. HC Wainwright currently has a “Buy” rating and a $19.00 target price on the stock. The consensus estimate for Acrivon Therapeutics’ current full-year earnings is ($2.49) per share. HC Wainwright also issued estimates for Acrivon Therapeutics’ Q2 2025 earnings at ($0.53) EPS, Q3 2025 earnings at ($0.54) EPS, Q4 2025 earnings at ($0.56) EPS, FY2025 earnings at ($2.30) EPS, FY2026 earnings at ($2.77) EPS, FY2027 earnings at ($2.31) EPS and FY2028 earnings at ($1.96) EPS.

Acrivon Therapeutics (NASDAQ:ACRV) last announced its quarterly earnings results on Thursday, March 27th. The company reported ($0.60) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.66) by $0.06.

Several other research analysts also recently commented on ACRV. KeyCorp initiated coverage on Acrivon Therapeutics in a report on Friday, January 31st. They set an “overweight” rating on the stock. Cantor Fitzgerald reissued an “overweight” rating on shares of Acrivon Therapeutics in a research report on Wednesday. Eight research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $23.17.

Acrivon Therapeutics Stock Down 11.1 %

Shares of Acrivon Therapeutics stock opened at $2.24 on Friday. The stock has a market cap of $69.74 million, a price-to-earnings ratio of -0.83 and a beta of 0.85. Acrivon Therapeutics has a twelve month low of $2.14 and a twelve month high of $11.90. The company’s fifty day moving average is $5.35 and its 200 day moving average is $6.53.

Institutional Investors Weigh In On Acrivon Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ACRV. Acorn Capital Advisors LLC bought a new position in shares of Acrivon Therapeutics in the fourth quarter worth $2,440,000. Exome Asset Management LLC bought a new position in Acrivon Therapeutics in the 3rd quarter worth $817,000. State Street Corp boosted its position in Acrivon Therapeutics by 26.4% during the 3rd quarter. State Street Corp now owns 225,896 shares of the company’s stock valued at $1,581,000 after acquiring an additional 47,233 shares in the last quarter. JPMorgan Chase & Co. raised its holdings in Acrivon Therapeutics by 548.3% in the third quarter. JPMorgan Chase & Co. now owns 33,991 shares of the company’s stock worth $238,000 after purchasing an additional 28,748 shares in the last quarter. Finally, OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in Acrivon Therapeutics by 29.7% in the fourth quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 102,784 shares of the company’s stock worth $619,000 after purchasing an additional 23,535 shares during the period. 71.62% of the stock is currently owned by institutional investors.

About Acrivon Therapeutics

Acrivon Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates.